THE INFLUENCE OF CYTOPROTECTIVE THERAPY ON 2-YEAR SURVIVAL OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND COMORBID PATHOLOGY
DOI:
https://doi.org/10.11603/1811-2471.2021.v.i3.12525Keywords:
myocardial infarction, comorbidity, cytoprotective therapy, survivalAbstract
Optimisation of therapeutic strategies for acute myocardial infarction in case of comorbidity is considered to be one of the actual directions of modern medicine. The implementation of this task is possible by the additional to standart treatment administration of cytoprotective therapy (quercetin, L-arginine) in the acute period of myocardial infarction, which is confirmed by analysis of 2-year survival of patients included in the study.
The aim – evaluation of long-term survival of patients with myocardial infarction and comorbid pathology, who were prescribed cytoprotective therapy in acute period additionally to standard protocol treatment.
Material and Methods. 506 patients with acute myocardial infarction admitted to Ternopil cardiology center were examined. Patients were divided into groups according to comorbid pathology. The groups were randomized into subgroups depending on the treatment performed in the acute period of myocardial infarction. The analysis of long-term survival of patients was performed according to the Kaplan-Meier method, the difference was assessed using the log-rank test (c²).
Results. The investigation showed better survival of patients after myocardial infarction who received L-arginine additionally to standard therapy in acute period. Survival rates according to the log rank test differed significantly (c²=2.20; p=0.001) from the group of basic therapy. The cumulative survival rate for patients receiving additional cytoprotective therapy (L-arginine or corvitin) also differed significantly from group receiving only protocol-based standard therapy (c²=14.28; p=0.001).
Conclusions. The results of a 2-year follow-up showed an improvement of long term survival of patients with myocardial infarction and comorbid pathology in distant postinfarction period who recieved cytoprotective therapy (L-arginine and quercetin) during the acute phase of disease.
References
Kovalenko, V.M., & Lutaj, M.I. (2020). Sercevo-sudynni zahvoryuvanja. Clasifikacija, standarty diagnostyky ta likuvanja [Cardiovascular desease. Classification, standards of diagnosis and treatment]. Kyiv: Morion [in Ukrainian].
Parxomenko, A.N., Lutaj, Ya.M., Irkin, O.I., Bilyi, D. O., Stepura, A. O., Kushnir, S.P., Skarzhevskyi, O.A., & Shumakov, O.V. (2018). Kliniko-anamnestychna kharakteristyka i perebig hospitalnoho periodu zakhvoriuvannia u hvoryh molodoho viku z hostrym koronarnym syndromom z elevaciieiu sehmenta ST [Clinical, anamnestic characteristics and course of in-hospital period in young patients with ST-elevation acute coronary syndrome]. Ukrainskij Kardіologіchnij Zhurnal – Ukrainian Journal of Cardilogy, 4, 31-39 [in Ukrainian].
Kovalenko, V.M., & Bortkevych O.P. (2019). Komorbidnist: vyznachennja, mozhlyvi naprjamky diagnostyky ta likuvannja [Comorbidity: Definition, possible ways to diagnostics and treatment]. Ukrainskij Revmatologichnij Zhurnal – Ukrainian Journal of Rheumatology, 3, 33-44 [in Ukrainian].
Baechlia, C., Kocha, D., Berneta, S., Gut , L., Wagner, U., Mueller, B., Schuetz, Ph., & Kutz, A. (2020) Association of comorbidities with clinical outcomes in patients after acute myocardial infarction. IJC Heart & Vasculature, 29, 550-558.
Ofori-Asenso, R., Zomer, E., Chin, K.L., Si, P. Markey S., Ademi, Z., Curtis, A. J., Zoungas, S., & Liew, D. (2019). Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. Cardiovasc. Diagn. Ther., 9, 250-261.
Batushkin, V.V. (2017). Tsytoprotektsiia pry hostromu infarkti miokarda pislia vidkryttia infarkt-zalezhnoi arterii: novi horyzonty [Cytoprotection in acute myocardial infarction after the discovery of a heart attack-dependent artery: new horizons]. Liky Ukrainy – Medicine of Ukraine, 8 (214), 33-40 [in Ukrainian].
Rezvan, V.V., & Vasiljeva, I.S. (2016). Rol metabolicheskoy terapiji v sovremennoy kardiologiji [Role metabolic treatment at modern cardiology]. Ryskij Medizindkij Zhurnal – Russian Medical Journal, 19, 1276-1280 [in Russian].
Taschuk, V.K., Ivanchuk, P.R., Polianska, O.S., Taschuk, K.H., & Savchuk, O.V. (2018). Osoblyvosti zastosuvannia metabolichnoi terapii u khvorykh na hostru ta khronichnu ishemichnu khvorobu sertsia: analiz tsyfrovoi obrobky elektrokardiohramy za dopomohoiu prohramnoho kompleksu «Smart-ECG». [Peculiarities of the metabolic therapy use in patients with acute and chronic ischemic heart disease: analysis of digital processing of electrocardiogram]. Klinichna ta eksperymental'na patolohiia – Clinical & experimental pathology, 17(2), 99-106 [in Ukrainian].
Kuriata, O.V., & Hrechanyk M.M. (2019). Rol L-argininu v likuvannji sercevo-sudynnyh zahvoryuvan: u fokusi – vybir efektyvnoj dozy [Role L-arginin at the treatment of cardiovascular deseases: in the focus is selection of the optimal dose]. Zdorovja Ukrainy – Health of Ukraine, № 11 (456), 17-18 [in Ukrainian].
Taschuk, V.K., Ivanchuk, P.R., Taschuk, M.V., Polianska, O.S., Amelina, T.M., Makoviichuk, I.O., Onofreychuk, D.I., & Shevchuk V.A. (2017). Kilkisna otsinka elektrokardiohramy v porivnyanni efektyvnosti kardioprotektsiyi pry hostromu infarkti miokarda [Quantitative evaluation of electrocardiogram in comparison of cardioprotection efficiency in acute myocardial infarction]. Bukovynskyi medychnyi visnyk – Bukovinian Medical Herald, 21, 94-99 [in Ukrainian].
Shved, M.I., Tsuglevich, L.V., Heryak, S.M., Kovbasa, N.M., Prokopovich, O.O., & Jastremska, O.I. (2019). Shliakhy pidvyshchennia efektyvnosti likuvannia ta profilaktyky reperfuziinoho syndromu u khvorykh na hostryi koronarnyi syndrom (infarkt miokarda), yakym provedeno balonnu anhioplastyku ta stentuvannia koronarnoi arterii [Ways for improvement of central and peripheral hemodynamics in patients with acute coronary syndrome (myocardial infarction), who underwent balloon angioplasty and stenting of the coronary artery]. Zdobutky klinichnoi i eksperementalnoi medytsyny – Achievements of Clinical and Experimental Medicine, 1, 173-181 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
